Adhera Therapeutics Stock

Adhera Therapeutics Stocks 2024

Adhera Therapeutics Stocks

2.31 M

Ticker

ATRX

ISIN

US00687E1091

In 2024, Adhera Therapeutics had 2.31 M outstanding stocks, a 254.91% change from the 650,180 stocks in the previous year.

The Adhera Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
20222.31
20210.65
20200.54
20190.54
20180.54
20170.49
20160.24
20152.46
20142.46
20132.46
20121.34
20110.63
20100.18
20090.09
20080.07
20070.06
20060.05
20050.05
20040.03
20030.03

Adhera Therapeutics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Adhera Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adhera Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adhera Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adhera Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adhera Therapeutics Aktienanalyse

What does Adhera Therapeutics do?

Adhera Therapeutics Inc was founded in California in 2015 and is a biopharmaceutical company that focuses on researching, developing, and commercializing therapeutics for the treatment of metabolic diseases. Translation: Adhera Therapeutics Inc was founded in California in 2015 and is a biopharmaceutical company that focuses on researching, developing, and commercializing therapeutics for the treatment of metabolic diseases. The history of Adhera Therapeutics Inc began with the goal of developing innovative and effective treatment options for metabolic diseases such as diabetes or high cholesterol levels. The company has utilized its expertise in drug development to explore novel therapeutics and medications that meet the needs of patients and improve their quality of life. Adhera Therapeutics Inc specializes in three main areas: diabetes, obesity, and cardiovascular diseases. Within these areas, the company has developed a variety of products aimed at lowering blood sugar and cholesterol levels, increasing insulin sensitivity, reducing appetite, and controlling body weight. The business model of Adhera Therapeutics Inc is based on the development of high-quality medications and therapies specifically tailored to the needs of patients with metabolic diseases. The company utilizes innovative technologies, advanced research methods, and sound scientific knowledge to develop medications that demonstrate high efficacy and clinical safety. Adhera Therapeutics Inc has introduced a variety of products to the market specifically developed for different types of metabolic diseases. These include insulin sensitizers that lower blood sugar levels and increase insulin sensitivity, which can be used in the treatment of type 2 diabetes. Another product is a GLP-1 agonist that contributes to appetite control and is used in the treatment of obesity. Adhera Therapeutics Inc has also developed a long-acting preparation that is administered weekly and can be used in the combination treatment of type 2 diabetes and obesity. The medication aims to lower both blood sugar levels and body weight while improving insulin sensitivity and reducing the risk of complications in diabetes. The company has also developed a medication for the treatment of hyperlipidemia that aims to reduce high cholesterol levels and lower the risk of cardiovascular diseases. Overall, Adhera Therapeutics Inc has developed an impressive range of products aimed at meeting the needs of patients with metabolic diseases and improving their quality of life. The company has conducted extensive scientific research and clinical studies to demonstrate the effectiveness and safety of its products. Adhera Therapeutics Inc has now achieved a strong position in the metabolic disease market and will continue to be innovative in exploring and developing new therapeutics and medications that improve the health of patients worldwide. Adhera Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Adhera Therapeutics's Shares Outstanding

Adhera Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Adhera Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Adhera Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Adhera Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Adhera Therapeutics stock

How many stocks are there of Adhera Therapeutics?

The current number of stocks of Adhera Therapeutics is 2.31 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Adhera Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Adhera Therapeutics evolved in recent years?

The number of shares of Adhera Therapeutics has increased by 254.91% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Adhera Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Adhera Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Adhera Therapeutics pay?

Over the past 12 months, Adhera Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adhera Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adhera Therapeutics?

The current dividend yield of Adhera Therapeutics is .

When does Adhera Therapeutics pay dividends?

Adhera Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adhera Therapeutics?

Adhera Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adhera Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adhera Therapeutics located?

Adhera Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adhera Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adhera Therapeutics from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Adhera Therapeutics pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Adhera Therapeutics in the year 2023?

In the year 2023, Adhera Therapeutics distributed 0 USD as dividends.

In which currency does Adhera Therapeutics pay out the dividend?

The dividends of Adhera Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adhera Therapeutics

Our stock analysis for Adhera Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adhera Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.